6月26日，羚锐制药获华福证券买入评级，近一个月羚锐制药获得1份研报关注。
研报预计羚锐制药作为国内知名中药贴膏品牌企业，龙头地位稳固。公司目前处于第二次营销改革阶段，业绩弹性将得到充分凸显，华福证券预计公司24-26年归母净利润将分别达到6.8/8/9.3亿元。研报认为，羚锐制药近年来，公司持续增加研发投入，注重研究化学贴片、骨科、心脑血管等领域，致力于推进已上市产品的二次开发。
风险提示：行业竞争加剧风险、新产品研发进度不及预期、原材料价格大幅波动风险。
- Headlines
- 羚锐制药获华福证券买入评级，中药贴膏龙头企业，营销改革凸显经营弹性
羚锐制药获华福证券买入评级，中药贴膏龙头企业，营销改革凸显经营弹性
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Hot News
Updated
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.